In 2022, the Cholesterol Monitors Market Size is anticipated to be valued US$ 2,514.6 million. The Cholesterol Monitors market is estimated to grow at a 7.4% CAGR and earn US$ 4,502.4 million between 2022 and 2032.
Rising obesity rates and an ageing population in industrialised countries like the United States, Germany, and France have resulted in an increase in the number of patients with high levels of bad cholesterol, necessitating a daily increase in global demand for cholesterol monitoring kits.
The global market for Cholesterol Monitors is predicted to expand due to the increasing adoption of non-invasive cholesterol monitoring methods.
Unlock growth potential with industry expertise. Download your market sample report now: https://www.futuremarketinsights.com/reports/sample/rep-gb-5400
Statistical Estimation in the Global Cholesterol Monitors Market:
- The growing elderly population is a major element driving the rise in demand for cholesterol monitor kits. According to the population division of the Department of Economic and Social Affairs, by 2050, there will be 21.1% more persons in the world who are 60 or older than there were in 1990 (9.2% to 11.7%).
- According to 2017 United Health Foundation data, 12.5% of persons aged 60 and up had elevated total cholesterol. This high incidence is projected to drive the Cholesterol Monitors market forward in the near future.
- Due to the fact that high cholesterol has no symptoms, thorough cholesterol testing is essential. These tests assess triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels in the blood. Blood cholesterol levels can aid in the prevention of peripheral artery disease, heart attack, and stroke.
- If a person has had a stroke, PAD, coronary heart disease, a family history of early CVD, being overweight, diabetes, having a cholesterol-related ailment, or having high blood pressure, their cholesterol levels should be tested. One in every six persons (16.3%) has high cholesterol (classified as 240 mg/dL or greater), according to the Centres for Disease Control and Prevention.
What are the Factors Propelling the Global Cholesterol Monitors Market?
The increased frequency of cardiovascular diseases, combined with a greater emphasis on early diagnosis and miniaturisation of Cholesterol Monitors, is likely to drive the worldwide cholesterol monitor market ahead. The inclination for self-monitoring to improve quality of life and lead a healthy lifestyle is another factor driving the growth of the global market for Cholesterol Monitors.
In addition, the market is predicted to expand as a result of increased attention on lowering the worldwide burden of cardiovascular illnesses, as well as initiatives for preventive healthcare practises such as screening and health check-up programmes.
Governmental changes that provide cutting-edge healthcare facilities, as well as awareness efforts that are anticipated to enhance testing standards, all contribute to the worldwide cholesterol monitor market’s growth.
Discover the Future of Cholesterol Monitors. Ask an Analyst and explore the statistical estimation in the global market: https://www.futuremarketinsights.com/ask-question/rep-gb-5400
Who are the Key Players in the Global Cholesterol Monitors Market?
Key players have entered into merger agreements to expand their portfolios and provide effective services which can assist in managing infectious diseases and uncontrollable levels of cholesterol.
- Roche and GenMark Diagnostics have agreed to merge in May 2021, with Roche acquiring GenMark in its entirety for $1.8 billion. Roche intends to enhance its offering of molecular diagnostics with GenMark’s expertise in syndromic testing. The firms expect that GenMark’sePlex systems will aid Roche in the management of infectious diseases and drug resistance.
- In May 2022, Zydus Lifesciences announced Bemdac, a Bempedoic Acid medication for the treatment of excessive levels of bad cholesterol.
- Nexlizet (bempedoic acid-ezetimibe), a cholesterol-lowering combination approved by the FDA in February 2020, is intended to decrease LDL cholesterol in individuals with high cholesterol or established atherosclerotic cardiovascular disease who have reached maximum-tolerated statin treatment.
Key Companies Profiled
- Roche Diagnostics
- PTS Diagnostics
- Omron Healthcare, Inc
- ACON Laboratories, Inc.,
- AccuTech, LLC
- Alere Inc.
- Siemens
- Medline Industries, Inc.
- Abaxis, Inc.
- ManthaMed
- Fisher Scientific
Purchase Now to Access Segment-specific Information, Uncover Key Trends, Drivers, and Challenges: https://www.futuremarketinsights.com/checkout/5400
Key Segments Covered in the Cholesterol Monitors Industry Survey
By Product Type:
- Single-sided COD Chip-On-Flex
- Other Chip-On-Flex Types
By End Users:
- Military
- Medical
- Aerospace
- Electronics
- Other Verticals
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs